| Completed | Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) Parkinson's Disease | Phase 1 | 2019-03-05 |
| Completed | A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Migraine | Phase 1 | 2016-09-01 |
| Completed | A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) Parkinson's Disease | Phase 1 | 2016-06-01 |
| Completed | A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (C Parkinson Disease | Phase 1 | 2016-06-01 |
| Completed | A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Hea Healthy | Phase 1 | 2016-01-01 |
| Completed | A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalatio Asthma | Phase 1 | 2015-12-01 |
| Completed | A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Smoking | Phase 1 | 2015-12-01 |
| Completed | Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) I Migraine | Phase 1 | 2015-11-01 |
| Terminated | Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) Refractory Epilepsy | Phase 2 | 2015-06-01 |
| Completed | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse Multiple Sclerosis, Acute Relapsing | Phase 1 | 2015-04-01 |
| Terminated | Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. Post-ischemic Stroke | Phase 3 | 2015-04-01 |
| Completed | Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Idiopathic Parkinson's Disease | Phase 3 | 2015-03-01 |
| Completed | Randomized Safety Study of CVT-301 Compared to an Observational Control Group Idiopathic Parkinson's Disease | Phase 3 | 2015-03-01 |
| Terminated | An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. Epilepsy | Phase 2 | 2014-12-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. Post-Ischemic Stroke | Phase 3 | 2014-12-01 |
| Completed | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Idiopathic Parkinson's Disease | Phase 3 | 2014-11-01 |
| Completed | A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Plac Heart Failure | Phase 1 | 2013-09-01 |
| Terminated | AC105 in Patients With Acute Traumatic Spinal Cord Injury Acute Spinal Cord Injury | Phase 2 | 2013-07-01 |
| Completed | Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes Idiopathic Parkinson's Disease | Phase 2 | 2013-04-01 |
| Completed | A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Spasticity | Phase 2 | 2013-04-01 |
| Completed | An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Multiple Sclerosis | Phase 1 | 2013-03-01 |
| Completed | Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Idiopathic Parkinson's Disease | Phase 2 | 2012-05-01 |
| Completed | A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemi Ischemic Stroke | Phase 2 | 2012-05-01 |
| Completed | An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Multiple Sclerosis | — | 2012-01-01 |
| Completed | Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy Cerebral Palsy (CP) | Phase 1 | 2011-12-01 |
| Completed | A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Se Epilepsy | Phase 2 | 2011-09-01 |
| Terminated | Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy Spasticity Due to Cerebral Palsy | Phase 1 | 2011-05-01 |
| Completed | Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Multiple Sclerosis | Phase 3 | 2011-03-01 |
| Completed | Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Insufficiency | Phase 1 | 2011-01-01 |
| Completed | Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure Heart Failure | Phase 1 | 2010-12-01 |
| Completed | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients Multiple Sclerosis | Phase 3 | 2007-08-01 |
| Completed | Study of Fampridine-SR Tablets in Multiple Sclerosis Patients Multiple Sclerosis | Phase 3 | 2007-05-01 |
| Completed | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis | Phase 3 | 2006-06-01 |
| Completed | Study of Oral Fampridine-SR in Multiple Sclerosis Multiple Sclerosis | Phase 3 | 2005-05-01 |
| Completed | Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients Multiple Sclerosis | Phase 3 | 2003-11-01 |
| Completed | Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis Multiple Sclerosis | Phase 2 | 2003-02-01 |
| Completed | Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury Spinal Cord Injury, Muscle Spasticity | Phase 3 | 2002-07-01 |
| Completed | Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From S Spinal Cord Injury, Muscle Spasticity | Phase 3 | 2002-06-01 |